773 results on '"DI MARCO, Vito"'
Search Results
2. Real-world experience with long-term albumin in patients with cirrhosis and ascites
3. A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort
4. Noninvasive Assessment of portal Hypertension in Patients With Primary Biliary Cholangitis is Affected by Severity of Cholestasis
5. Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease
6. Adverse events in gastrointestinal endoscopy: Validation of the AGREE classification in a real-life 5-year setting
7. AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD
8. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination
9. Development of a Thalassemia International Prognostic Scoring System (TIPSS)
10. Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis
11. Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study
12. Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies
13. Effectiveness of a screening program for HBV, HCV, and HIV infections in African migrants to Sicily
14. Clinical outcomes of MAFLD versus NAFLD: A meta‐analysis of observational studies.
15. What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg‐negative anti‐HBc‐positive patients? Meta‐analysis and decision curve analysis.
16. Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence
17. SAT-113 Long-term therapy with intravenous human albumin increase survival in patients with decompensated cirrhosis and refractory ascites
18. FRI-078-YI Long-term albumin administration in outpatients with decompensated cirrhosis and diabetes mellitus: post-hoc analysis of the ANSWER trial database
19. FRI-047-YI Predictors of ascites resolution in patients with cirrhosis receiving long-term albumin treatment. Results from a real-world study in Italy (Real-ANSWER)
20. SAT-209-YI A Markov model unveiling the impact of Resmetirom on the natural history of MASLD patients with baseline significant or severe liver fibrosis
21. Factors Associated with Primary Liver Cancer Survival in a Southern Italian Setting in a Changing Epidemiological Scenario
22. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP)
23. PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease
24. Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes
25. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease
26. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites
27. Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease
28. Adult to Adult Living Donor Liver Transplantation in Recipients with Low MELD: A Strategy Intended to Overcome Donor Shortage
29. Update of the statements on biology and clinical impact of occult hepatitis B virus infection
30. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients
31. Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group
32. Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis
33. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents
34. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis
35. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial
36. Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients
37. Risk of liver-related events in metabolic dysfunction–associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria
38. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity
39. Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel
40. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication
41. Risk of liver-related events in metabolic dysfunction–associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria.
42. Current and future challenges in HCV: insights from an Italian experts panel
43. Epidemiological and clinical profile of HDV infected people in care in Italy: interim analysis from the ongoing PITER cohort
44. Programmed cell death 1 genetic variant and liver damage in non-alcoholic fatty liver disease
45. Real-word experience of long-term albumin treatment in a large cohort of patients with cirrhosis and ascites (Real-Answer study)
46. Presence and severity of esophageal varices drives portal hypertension-related complications in compensated advanced non-alcoholic fatty liver disease
47. Long-term outcomes of patients with chronic HBsAg positive/HBe-negative infection: differences and transition between inactive carriers and low viremic carriers
48. RESIST criteria accurately rule-out high-risk esophageal varices in patients with primary biliary cholangitis and compensated advanced chronic liver disease
49. Risk factors for viral reactivation in patients with overt or occult HepatitisB Virus infection receiving immunosuppressive treatments: a systematic review and meta-analysis
50. Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.